Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 15, 2006

View Archived Issues

Effects of magnolol on glucosyltransferase explored

Bortezomib/LBH-589 cytotoxicity synergistic in multiple myeloma cells

Antigenics reveals progress in key programs

Dopamine bioactive material as a potential nerve regeneration therapy

Janssen selects Invega as brand name for paliperidone extended release tablets

Pilot trial of Celaderm cleared to begin enrollment

VariZIG awarded orphan drug designation

Aricept studied in pediatric brain cancer survivors

NGD-4715 enters clinic for obesity

Medarex to receive milestone payment from Amgen

CTA-018 cream studied in patients with chronic plaque psoriasis

Phase III AML study of Cloretazine reaches interim analysis

Dendreon completes rolling BLA for Provenge

AVT-01 for asthma begins phase IIa studies

Fast track designation for OncoVAX in colon cancer

Updated phase II results for TG-4001 in CIN 2/3

Positive preclinical and clinical data of AD-452 in rheumatoid arthritis

Pfizer's novel Chk1 inhibitor enhances cytotoxicity of chemotherapeutic agents

Nerviano's novel Cdc7 inhibitor possesses antitumor activity in preclinical studies

Targeting PIN1: a novel strategy in cancer therapy

Emerging companies showcased at BIO-Europe 2006: Heidelberg Pharma

Emerging companies showcased at BIO-Europe 2006: Pelias

Humira receives approval for expanded indication in psoriatic arthritis

Zinc-based compound has antiproliferative and apoptotic effects in gynecological tumors in vitro

Trials support dose and schedule of combination of eniluracil + 5-FU

FavId interim data: nearly 50% of patients achieve complete remission over time

Clobazam shows potential in the treatment of Lennox-Gastaut syndrome

New agents for treating neurological disorders disclosed in recent patent literature

Recent patents disclose new therapeutic agents for anxiety, depression, etc

New agent for glaucoma disclosed in recent Johns Hopkins University patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...